Tatzer E, Groh C
Padiatr Padol. 1980;15(4):293-6.
41 patients receiving Carbamazepine under regular measurements of blood levels were compared with 77 patients with no or irregular controls of the blood level. 71% of the patients in the first group had a good seizure control in contrast to 61% of the patients in the second group. Furthermore, patients with regular controls reached the desired therapeutical effect earlier (on an average within 21/2 months) compared with patients with no or irregular controls (the average was 10 months). Patients who did nor react to medication with CBZ were put on another drug within a shorter time if their blood levels were measured (on the average 10 months compared with 20 months). We conclude that regular blood level controls make handling of CBZ easier. This allowed us to extend the range of indications for CBZ to a greater number to epilepsy with grand mal and focal seizures as well as to few therapy-resistant cases of epilepsy of early childhood with tonic seizures.
41例接受卡马西平治疗并定期监测血药浓度的患者与77例未进行血药浓度监测或监测不规律的患者进行了比较。第一组中71%的患者癫痫得到了良好控制，而第二组中这一比例为61%。此外，与未进行监测或监测不规律的患者相比（平均为10个月），定期监测血药浓度的患者更早达到预期治疗效果（平均在2个半月内）。如果对卡马西平治疗无反应的患者进行了血药浓度监测，那么他们会在更短时间内换用其他药物（平均10个月，而未监测者为20个月）。我们得出结论，定期监测血药浓度使卡马西平的应用更便捷。这使我们能够将卡马西平的适应证范围扩大到更多的癫痫大发作、局灶性发作患者，以及少数儿童早期难治性强直发作癫痫患者。
